We are live on ! Find out more
AKYA

Akoya BioSciences

Delisted

AKYA was delisted on the 7th of July, 2025.

59 hedge funds and large institutions have $29M invested in Akoya BioSciences in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 20

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

5.15% less ownership

Funds ownership: 30.23%25.08% (-5.2%)

13% less funds holding

Funds holding: 6859 (-9)

56% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 16

58% less capital invested

Capital invested by funds: $69.7M → $29M (-$40.7M)

Holders
59
Holders Change
-9
Holders Change %
-13.24%
% of All Funds
0.85%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
7
Increased
21
Reduced
20
Closed
16
Calls
$180K
Puts
Net Calls
+$180K
Net Calls Change
-$200K
Name Holding Trade Value Shares
Change
Change in
Stake
BWLSA
1
Blue Water Life Science Advisors
California
$11M
BlackRock
2
BlackRock
New York
$3.51M +$492K +154,348 +11%
Vanguard Group
3
Vanguard Group
Pennsylvania
$3.43M +$30.5K +9,565 +0.7%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$1.32M +$153K +48,074 +9%
SW
5
SVB Wealth
Massachusetts
$1.21M
State Street
6
State Street
Massachusetts
$1.02M +$21.1K +6,608 +2%
PHP
7
Parkman Healthcare Partners
Connecticut
$879K -$1.73M -541,906 -59%
PAPAIJV
8
Paragon Associates & Paragon Associates II Joint Venture
Texas
$819K +$1.12M +350,000 New
PCH
9
Polar Capital Holdings
United Kingdom
$772K -$3.99M -1,250,000 -79%
SSA
10
Schonfeld Strategic Advisors
New York
$689K -$259K -81,158 -22%
PCA
11
Peddock Capital Advisors
Massachusetts
$550K -$16.3K -5,124 -2%
Northern Trust
12
Northern Trust
Illinois
$491K +$7.41K +2,322 +1%
BCM
13
Bridgeway Capital Management
Texas
$420K +$507K +159,100 +776%
Charles Schwab
14
Charles Schwab
California
$412K +$13.1K +4,112 +2%
GCP
15
GSA Capital Partners
United Kingdom
$388K +$478K +150,001 +951%
OCM
16
Osterweis Capital Management
California
$295K
Morgan Stanley
17
Morgan Stanley
New York
$253K +$142K +44,418 +70%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$158K +$30.1K +9,429 +16%
Squarepoint
19
Squarepoint
New York
$154K -$231K -72,329 -52%
ZIC
20
ZWJ Investment Counsel
Georgia
$109K +$4.15K +1,300 +3%
Jane Street
21
Jane Street
New York
$105K +$99.7K +31,262 +232%
N
22
Nuveen
North Carolina
$95.5K
QC
23
Quadrature Capital
United Kingdom
$92.9K +$127K +39,891 New
AllianceBernstein
24
AllianceBernstein
Tennessee
$77.3K +$18.8K +5,900 +22%
RhumbLine Advisers
25
RhumbLine Advisers
Massachusetts
$67.2K -$16.3K -5,125 -15%

AKYA Hedge Fund Activity: Q2 2024 in Review

59 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Akoya BioSciences (AKYA) for Q2 2024, worth a combined $29M — down 58% from $69.7M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of AKYA and 7 opened new positions — a net loss of 9 holders — while 20 trimmed existing stakes and 21 added.

The largest buyer was Paragon Associates & Paragon Associates II Joint Venture, opening a new position worth an estimated $1.12M. The largest seller was Polar Capital Holdings, cutting an estimated $3.99M.

  • 59 institutional investors held Akoya BioSciences (AKYA) as of Q2 2024, down from 68 in Q1 2024.
  • Funds reported $29M of Akoya BioSciences stock for Q2 2024, down 58% quarter-over-quarter.
  • 7 funds opened new Akoya BioSciences positions in Q2 2024 and 16 closed out, a net change of -9 holders.
  • The largest Akoya BioSciences buyer in Q2 2024 was Paragon Associates & Paragon Associates II Joint Venture, an estimated $1.12M added.
  • The largest Akoya BioSciences seller in Q2 2024 was Polar Capital Holdings, an estimated $3.99M sold.

Based on aggregated 13F filings for Q2 2024.